MedTrace Logo

Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer

NCT00470574 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2020-11-18

Study results available
· View outcomes & findings →

Summary

RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy together with QS21 may cause a stronger immune response and kill more tumor cells.

PURPOSE: This clinical trial is studying the side effects and how well giving vaccine therapy together with QS21 works in treating patients with metastatic breast cancer.

Conditions

Interventions

BIOLOGICAL

QS21

BIOLOGICAL

sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine

OTHER

immunoenzyme technique

OTHER

immunologic technique

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

Principal Investigators

  • Teresa Ann Gilewski, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-20
Primary Completion
2020-01-24
Completion
2020-01-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00470574 on ClinicalTrials.gov